Sunny Pharmtech

Sunny Pharmtech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is 55.50 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 169.13 % — a change of -67.19% (lower).

FCF Conversion

55.50 %

YoY

-67.19%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sunny Pharmtech is 2024 55.50 % . FCF Conversion Rate (FCF/EBITDA) of Sunny Pharmtech was 2023 169.13 % . It decreases by -67.19% lower compared to the previous year.

The Sunny Pharmtech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
190.65 TWD
Jan 1, 2019
86.93 TWD
Jan 1, 2020
93.23 TWD
Jan 1, 2021
111.49 TWD
Jan 1, 2022
98.93 TWD
Jan 1, 2023
169.13 TWD
Jan 1, 2024
55.50 TWD
The Sunny Pharmtech FCF Conversion history
YEARFCF ConversionYoY
55.50 %-67.19%
169.13 %+70.97%
98.93 %-11.27%
111.49 %+19.58%
93.23 %+7.25%
86.93 %-54.40%
190.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

FCF Conversion Rate (FCF/EBITDA) of Sunny Pharmtech is 55.50 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Sunny Pharmtech changed from 169.13 % to 55.50 %, representing a -67.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech